Worth reading
34Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Avoiding a definitive answer
How definitive the wording is.This transaction
Succession of the business covered by this transactionCounterpartyKYORIN Pharmaceutical Co.,Ltd., 2 other companies (names not disclosed)
Disclosing companyDaito Pharmaceutical Co.,Ltd.
The voting-rights ratio is the share of the votes exercisable at a shareholders’ meeting that will be held after this transaction.The percentage before the change is not stated in this document.
TimelineThe spacing between the points is proportional to the actual number of days.White points represent dates designated as scheduled dates in the document.
Target company
Manufacture and sale of pharmaceuticals, etc.
Location Kanazawa, Ishikawa PrefectureShare capital ¥100 millionDate of incorporation 15 October 1947
Net Sales¥34,285 million (fiscal year ended March 2025)
Net income for the current fiscal yearNet loss of ¥519 million (fiscal year ended March 2025)
Net assets¥5,490 million (fiscal year ended March 2025)
Consideration and expenses
Funding arrangementsThe company is expected to be established through joint investment with 2 other companies, with ダイト as the largest investor without exceeding 50%; no specific source of funds for ダイト is disclosed.
Impact on Business Performance
The impact on consolidated results for the current fiscal year is not recognized at this time. The impact on results over the medium to long term will be disclosed again after execution of the definitive agreement.
Procedures and assumptions
Management structure after acquisitionThe policy is to pursue the integration of marketing authorizations and trade names with government support. The company states that it will pursue these efforts together with everyone engaged in the business covered by this transaction.
| Item | Details |
|---|---|
| Transaction name | Succession of the business covered by this transaction |
| Counterparty name | KYORIN Pharmaceutical Co.,Ltd., 2 other companies (names not disclosed) |
| Name of the Subject Company | キョーリン リメディオ株式会社 |
| Business Description of the Subject Company | Manufacture and sale of pharmaceuticals, etc. |
| Location of the Subject Company | Kanazawa, Ishikawa Prefecture |
| Capital Stock of the Subject Company | ¥100 million |
| Date of Establishment of the Subject Company | 15 October 1947 |
| Net Sales of the Subject Company | ¥34,285 million (fiscal year ended March 2025) |
| Net Income of the Subject Company | Net loss of ¥519 million (fiscal year ended March 2025) |
| Net Assets of the Subject Company | ¥5,490 million (fiscal year ended March 2025) |
| Voting rights ownership percentage | After Largest investor, with no more than 50% (percentage not disclosed) (before not disclosed) |
| Funding arrangements | The company is expected to be established through joint investment with 2 other companies, with ダイト as the largest investor without exceeding 50%; no specific source of funds for ダイト is disclosed. |
| Impact on Business Performance | The impact on consolidated results for the current fiscal year is not recognized at this time. The impact on results over the medium to long term will be disclosed again after execution of the definitive agreement. |
| Date of board resolution | 24 April 2026 |
| Contract Date | 24 April 2026 (date of execution of the basic agreement) |
| Execution Date / Effective Date | 1 April 2027 (予定) |
| Management structure after acquisition | The policy is to pursue the integration of marketing authorizations and trade names with government support. The company states that it will pursue these efforts together with everyone engaged in the business covered by this transaction. |
Items this document does not state (15)
Operating Profit of the Subject CompanyAcquisition priceExpenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredGoodwill amountAmount of extraordinary income (loss)Valuation methodologyIndependent valuation institutionSpecial CommitteeConditions Precedent to Execution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The aim is to promptly resolve concerns over the supply of generic drugs and establish a sustainable business foundation and stable supply system. ダイト states that it will promote the initiatives set out in DTP2027, including improving the efficiency of its existing businesses and pursuing alliances to strengthen the stable supply system for generic drugs, thereby strengthening its business foundation as an R&D-focused CMO company.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.